Transaction · 0001636282-26-000107
SYRESpyre Therapeutics, Inc.
Turtle Cameron
Turtle Cameron, CEO, reported an open-market or private sale at Spyre Therapeutics, Inc. involving 2500.000000 shares for an estimated $215900.00. Reported holdings after the transaction were 565040.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Open-market sellSEC transaction code SCEO
- Trade date
- Sep 01, 2026
- Filing date
- Sep 04, 2026
How reported position traded is calculated
Shares sold ÷ (holdings after + shares sold). Estimated position before: 567,540 shares.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
SYRE price since this filing
Daily closing prices, with the filing date and available return windowsSYRE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +10.5%1w ago +22.2%1d ago +0.4%
Returns since7d +1.8%30d +4.7%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- Sell Code S
- Identifier
- 0001636282-26-000107 Common Stock
- Transaction date
- Sep 01, 2026 Filed Sep 04, 2026, 01:33 AM · 3d delay
- Shares
- 2,500 sh $86.36 per share
- Estimated value
- -$215k Computed from shares × price
- Holdings after
- 565,040 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Sale 10b5-1 Detected
Filing-only score
-4 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Executive Officer
Officer YesDirector Yes10% NoOther No
Footnotes & amended
- F1
This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
- F2
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.67 to $86.66, inclusive. The Reporting Person undertakes to provide to
the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate p…
within the range.
- F3
Includes 43,593 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
- F4
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.67 to $87.65, inclusive. The Reporting Person undertakes to provide to
- (3 footnotes)
the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.68 to $88.67, inclusive. The Reporting Person undertakes to provide to
- F6
The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to
Related transactions
Same SEC filing0 other transactions
Recent company activity
SYRE0 recent txs